Health Summit 2025

- As transatlantic tariffs hits, how can the EU ensure a continuous and resilient supply of critical medicines across the bloc and mitigate economic turbulence?
- What measures should be implemented to reduce the risk of future medicine shortages, especially in the context of geopolitical instability and supply chain disruptions?

- How can Europe stay competitive in the global life sciences and biotech sectors while maintaining high standards of patient safety and ethics?
- What policy adjustments can enhance Europe’s attractiveness to biotech startups, SMEs, and multinational pharmaceutical companies?

- What actions can EU stakeholders take to drive bold leadership, improve prevention, and ensure early diagnosis and effective management of cardiometabolic conditions?
- Can Europe create a "Europe’s Beating Cardiovascular Disease Plan" similar to the "Europe’s Beating Cancer Plan"?

- How do disparities in healthcare access, treatment, and outcomes across member states contribute to overall health inequalities among different population groups and what can the EU do to mitigate this?
- What policy and systemic changes are needed to ensure equitable healthcare for both women and men across the EU, considering factors such as medical research, reproductive health, and chronic disease management?

- What is the economic burden of neurological diseases in Europe, and how could a European Neurological Health Strategy help reduce it? In what ways could such a strategy strengthen workforce resilience and support Europe’s economic competitiveness?
- In light of the severe shortage of healthcare workforce in neurology across Europe, what existing opportunities can Europe leverage to uphold its commitment to enhancing healthcare for neurological conditions – particularly considering the implications for Europe's projected trajectory of incidence and ageing?

- How can the EU and Member States enhance cross-border collaboration to improve diagnosis, research, and equitable access to treatment for rare disease patients?
- What policy, funding, and IP reforms are needed to accelerate the development and approval of orphan drugs while ensuring affordability and accessibility across Europe?
- What role should a European Action Plan on Rare Diseases play in addressing unmet needs and driving coordinated action at both national and EU levels?

- How can Europe leverage digital transformation and AI to drive innovation in healthcare while ensuring equitable patient access to these technologies?
- What regulatory frameworks are needed to foster innovation, support SMEs, and protect patients in the digital and AI-driven healthcare sector?